nuevaonco.com

AREAS | Acromegalia | Artículos

<<

Home

Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly.
	Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly.
Clinical review 154: The role of pharmacotherapy in perioperative management of patients with acromegaly.	Population pharmacodynamic analysis of octreotide in acromegalic patients.


	Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide.


	Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas


	Pituitary and adrenal disorders complicating pregnancy.


	Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre


	Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly


	The role of somatostatin analogues in the treatment of hypophyseal adenomas


	Pharyngeal pituitary non-functioning adenoma with normal intra-sellar gland: massive tumor shrinkage on octreotide therapy.


	Suppression of insulin secretion is associated with weight loss and altered macronutrient intake and preference in a subset of obese adults.


	Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas


	Somatostatin analogues as drug therapies for retinopathies.


	Effect of Sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity


	Octreotide LAR treatment throughout pregnancy in an acromegalic woman

© Novartis Farmaceutica SA. | Contacto | Aviso Legal | Poltica de Privacidad |